Volume : 8
Issue : S1
Tocilizumab treatment and outcomes in severe COVID-19 patients: Retrospective study from a tertiary care institute in western India
Peta RK, Panchal HP, Patel A, Parikh S, Khanikar D, Himthani N
Pdf Page Numbers :- 6-10
Ravindra Kumar Peta1,*, Harsha P Panchal1,*, Apurva Patel1, Sonia Parikh1, Duncan Khanikar1, and Nikhil Himthani1
1Department of Medical Oncology, The Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India
*Corresponding authors: Dr. Harsha P Panchal, Prof and HOD, Department of medical oncology, The Gujarat Cancer REsearch Institute, Ahmedabad, Gujarat, India. Mobile: +91 9825940769; Email: firstname.lastname@example.org. Dr. Ravindra Kumar Peta (DM Medical oncology), Resident, Department of Medical Oncology, The Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India. Mobile: +91 9023739722; Email: Ravindra0504090@gmail.com
Received 24 September 2020; Revised 9 November 2020; Accepted 17 November 2020; Published 25 November 2020
Citation: Peta RK, Panchal HP, Patel A, Parikh S, Khanikar D, Himthani N. Tocilizumab treatment and outcomes in severe COVID-19 patients: Retrospective study from a tertiary care institute in western India. J Med Sci Res. 2020; 8(S1):6-10. DOI: http://dx.doi.org/10.17727/JMSR.2020/8S1-1
Copyright: © 2020 Peta RK et al. Published by KIMS Foundation and Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
View Full Text
Background: Coronavirus disease 2019 (COVID-19) is a pandemic caused by a novel beta coronavirus severe acute respiratory syndrome coronavirus (SARS-CoV-2). The symptoms range from mild to severe in nature. The severity of respiratory symptoms is due to the cytokine storm. The tocilizumab, interleukin-6 inhibitor, can prevent the cytokine release and decrease the mortality.
Patients and methods: This is a retrospective observational study of 20 COVID-19 positive cases who received tocilizumab.
Results and conclusion: There were 75% males with a mean age of 47.20±9.68 years in our study. 50% had diabetes mellitus, 35% had hypertension, 5% had Chronic kidney disease, 5% had obesity and 5% had hypothyroidism. Mortality was reduced to 65% with tocilizumab administration. There was statistically significant reduction of C- reactive protein (p<0.00052) and IL-6 (interleukin) (p<0.023) after administration of tocilizumab.
Keywords: tocilizumab; interleukin-6; COVID-19; C-reactive protein